Labcorp (LH) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.Need a quote from one of our analysts? Email pr@fool.comLabcorp (NYSE:LH) reported double-digit top-line growth and margin expansion for fiscal Q2 2025, raising full-year 2025 guidance and attributing performance to continued strength in diagnostics and momentum in biopharma laboratory services. Management highlighted integration of key acquisitions, expanded strategic partnerships with major health systems, and enhanced specialty test offerings, particularly in oncology and neurology. The BLS segment demonstrated booking strength with a robust backlog in Q2 2025, while the Diagnostics segment delivered higher volume and improved price mix amid continued operational efficiency. Capital allocation in Q2 2025 prioritized investments, dividends, and buybacks while maintaining gross leverage at the low end of the targeted range. Management remains focused on navigating potential legislative headwinds such as PAMA in 2026.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool